FTM
BECOME A MEMBER
() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: Pascal Biosciences

  • Home
  •  | 
  • Tag Archives: "Pascal Biosciences"

Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer

Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, is pleased to announce that the Company has entered into an exclusive license agreement with the University of Washington (UW) in Seattle to develop a cannabinoid-based product for the treatment of glioblastoma multiform and brain metastases. The program, developed in the lab of renowned cannabis researcher Dr. Nephi Stella, founder and co-director of the UW Center for Cannabis Research, includes a lead therapeutic, ST-403. Pascal plans to begin human clinical studies of ST-403 in 2019.
Read more

Pascal Biosciences grants options to buy 2.1M shares

Pascal Biosciences grants options to buy 2.1M shares
Pascal Biosciences Inc. has granted an aggregate of 2.1 million stock options to directors, employees and consultants of the company, pursuant to the company's stock option plan and subject to the policies of the TSX Venture Exchange. The stock options are exercisable at a price of 35 cents per optioned share.
Read more